
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine Inc has demonstrated a significant enhancement in its pipeline prospects, particularly with the increased probability of FDA approval for bitopertin, now at 100%, following strong trial results showcasing its efficacy in reducing PPIX. Additionally, the company anticipates notable revenue growth, estimating sales of $35 million in 2026, escalating to $615 million by 2029, driven by an updated outlook on the launch of bitopertin and the favorable risk/reward scenario for DISC-0974. The recognition of a Commissioner’s National Priority Voucher further accelerates the review timeline for bitopertin, positioning the company to capitalize on market opportunities more swiftly.
Bears say
Disc Medicine Inc. faces significant challenges that contribute to a negative outlook on its stock. The company's pipeline, particularly the lead candidate bitopertin, may encounter hurdles related to regulatory approval and clinical efficacy, as concerns arise over the endpoints employed in Phase 3 trials, which could hinder the detection of a significant treatment benefit. Additionally, with limited cash reserves, the company may struggle to finance the development and commercialization of its products, further complicating its ability to advance its clinical programs efficiently.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares